# Myelo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myelo-therapeutics

- Industry: Healthcare Specialists
- Headquarters: Berlin, Germany
- Website: www.myelotherapeutics.com
- Latest round: Series B (Jan 8, 2016)
- Investors on record: 5

## About

Myelo Therapeutics GmbH is a Berlin-based biopharmaceutical company focused on developing medical countermeasures and therapies to mitigate the adverse effects of radiation exposure and chemotherapy for cancer patients.Myelo Therapeutics specializes in creating medical countermeasures for radiation exposure and supportive therapies for cancer treatment. The company has maintained a consistent strategy without significant pivots and is not known to have subsidiaries or parent companies. It was established in Berlin, Germany. The CEO is Dirk Pleimes, who has a background indicative of experience in biopharmaceutical ventures. In June 2020, Myelo Therapeutics raised Venture funding led by returning investor Eckert & Ziegler. Financial terms were not disclosed, making the company the investment target with a total of 7 deals noted.Myelo Therapeutics GmbH specializes in the development of medical countermeasures and cancer-supportive care therapies designed to address the adverse effects of radiation exposure and chemotherapy. The company's core products aim to protect the public from lethal radiation attacks and offer therapeutic support for cancer patients experiencing unintended chemotherapy-related effects. Their innovative solutions are targeted toward healthcare facilities, hospitals, and governmental agencies that require advanced medical interventions in the event of radiation incidents. The products serve various geographical markets, including North America and Europe, where awareness of radiation safety and oncology care is heightened.The revenue structure of Myelo Therapeutics GmbH encompasses several transactional models, primarily focusing on B2B partnerships with healthcare providers and governmental organizations. Transactions are facilitated through direct procurement agreements, enabling clients to acquire the company's flagship medical countermeasures and therapies suited for specific medical scenarios. Clients, including hospitals and cancer treatment centers, engage in contractual agreements outlining the purchase of products based on their therapeutic needs and available medical protocols. Pricing plans for these products are structured to accommodate institutional budgets while ensuring access to essential medical resources, facilitating a steady flow of revenue through ongoing partnerships and supply agreements.Myelo Therapeutics plans to expand its product line with new therapies focused on enhancing recovery from chemotherapy and radiation exposure. The company aims to enter additional markets in Asia and South America by 2023, informed by increasing demand for radiation safety products. The recent Venture funding raised in June 2020, though financial terms were not disclosed, will support these expansion initiatives and product developments, allowing the company to enhance its capacity to meet global healthcare needs.

## Funding rounds

- Series B, Jan 8, 2016 — IBB Ventures, JSC Valenta Pharmaceuticals, VC Fonds Technologie Berlin, Eckert Life Science Accelerator
- Series A, Sep 25, 2013 — IBB Ventures, JSC Valenta Pharmaceuticals, Eckert Wagniskapital und Frühphasenfinanzierung GmbH

## Investors

- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Series A, Series B
- JSC Valenta Pharmaceuticals — Series A, Series B
- Eckert Wagniskapital und Frühphasenfinanzierung GmbH — Series A
- VC Fonds Technologie Berlin — Series B
- Eckert Life Science Accelerator — Series B